Gastric Cancer: The efficacy and safety of nivolumab in the treatment of unresectable advanced or recurrent gastric/gastric junction cancer (G/GEJ): real research data from Japan

Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death in the world
.

In Japan, stomach cancer is the third most common cause of cancer-related deaths

Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death in the world

This multi-center observational study was conducted in 158 centers in Japan
.

Enrolled patients with unresectable advanced or recurrent G/GEJ cancer registered between November 1, 2017 and October 31, 2018, and explored background characteristics and treatment-related adverse events (TRAEs) and treatment-related adverse events (TRAEs) 6 months after the start of nivolumab treatment Correlation of tumor response

This multi-center observational study was conducted in 158 centers in Japan

Overall, a total of 654 patients were registered (safety analysis set, n = 650; effectiveness analysis set, n = 636; efficacy evaluation set, n = 516)

205 (31.

TRAEs

TRAEs

Multivariate analysis found that TRAEs had significant and no peritoneal metastasis (p = 0.
0494); past or current comorbidities (p = 0.
0259), including lung disease (p = 0.
0055), thyroid disease (p = 0.
0287) , Is related to patients with kidney disease (p = 0.
0189)
.

Multivariate analysis found that TRAEs had significant and no peritoneal metastasis (p = 0.
0494); past or current comorbidities (p = 0.
0259), including lung disease (p = 0.
0055), thyroid disease (p = 0.
0287) , Is related to patients with kidney disease (p = 0.
0189)
.

In the efficacy evaluation set (n = 516), the tumor response was CR 6 cases (1.
2%), PR 52 cases (10.
1%), SD 140 cases (27.
1%), PD 301 cases (58.
3%), not evaluated (NE ) 17 cases (3.
3%)
.

The 6-month survival rate was 52.

In the efficacy evaluation set (n = 516), the tumor response was CR 6 cases (1.

ORR was evaluated in 499 patients

In summary, the real-world research data show that the efficacy and safety of nivolumab in the treatment of unresectable advanced or recurrent gastric/gastroesophageal junction cancer (G/GEJ) and the phase III study ATT RAC TION -2 is consistent

Original source:

Kensei Yamaguchi, Narikazu Boku, Kei Muro, et al.

Kensei Yamaguchi, Narikazu Boku, Kei Muro, et al.
Real‑world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study.
Gastric Cancer.
https:/ /doi.
org/10.
1007/s10120-021-01244-y leave a message here